ZEUS System vs prolaio eVO2peak Module
AI Verdict
Choose ZEUS System if…
Choose ZEUS System if your primary objective is long-term, continuous cardiac monitoring for the detection and characterization of arrhythmias, such as Atrial Fibrillation. This tool is ideal for identifying both symptomatic and asymptomatic cardiac events over an extended period, providing detailed ECG analysis and preliminary reports to aid in early diagnosis and management.
View ZEUS System →Choose prolaio eVO2peak Module if…
Choose prolaio eVO2peak Module if your focus is on assessing cardiorespiratory fitness and estimating peak oxygen consumption (eVO2peak) for cardiovascular risk stratification, rehabilitation planning, or research purposes. This software is best suited for leveraging existing compatible wearable sensor data to provide an adjunctive aid in clinical evaluation of a patient's functional capacity.
View prolaio eVO2peak Module →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | ZEUS System | prolaio eVO2peak Module |
|---|---|---|
| Pricing | Not disclosed | Contact for pricing |
| Deployment | Cloud-based (AWS EC2 platform), no on-premise hardware. | Cloud-based (software-only, processes remote sensor data) |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ZEUS SystemThe ZEUS System (Tool A) offers preliminary report generation for physicians and explicit HL7-based EHR integration, suggesting a streamlined workflow within its ecosystem. Its integration with proprietary Zio monitors provides a cohesive user experience. In contrast, prolaio eVO2peak Module (Tool B) processes data from qualified third-party sensors, which could introduce variability in the user experience depending on the specific sensor used.
Clinical Value
ZEUS SystemBoth tools are FDA-cleared and address significant cardiovascular needs. The ZEUS System (Tool A) directly aids in the detection and characterization of arrhythmias like Atrial Fibrillation through continuous ECG monitoring, offering immediate diagnostic value. While the prolaio eVO2peak Module (Tool B) provides valuable eVO2peak estimation as an adjunctive aid, the direct diagnostic capability of Tool A for a specific condition offers a more actionable clinical impact.
Pricing & Value
TieNeither tool discloses its pricing information in the provided facts. Tool A states 'not disclosed' and Tool B states 'contact for pricing,' making a direct comparison of their pricing and overall value impossible without further details.
Enterprise Readiness
ZEUS SystemBoth tools are cloud-based, FDA-cleared, HIPAA compliant, and have BAAs. However, the ZEUS System (Tool A) explicitly highlights 'HL7-based EHR integration' as a key feature. This direct mention of a standard for electronic health record integration gives Tool A a clear advantage in terms of readiness for seamless adoption within larger healthcare enterprise systems.
Innovation
prolaio eVO2peak ModuleWhile both leverage AI, the prolaio eVO2peak Module (Tool B) demonstrates a more novel application by estimating peak oxygen consumption (eVO2peak) using a locked deep-learning model from diverse inputs like demographic data, single-lead ECG, and triaxial accelerometry from remote wearable sensors. This non-invasive estimation of a complex physiological parameter from real-world data represents a significant innovative leap compared to enhancing an existing cardiac monitoring paradigm.
Support & Docs
ZEUS SystemiRhythm Technologies (Tool A) explicitly offers 24/7 patient support via phone and email, along with dedicated provider support. Prolaio (Tool B) indicates a 'Clinical Support & Zendesk Specialist' role to handle support requests via phone, email, and tickets, and provides a general contact email. The explicit mention of 24/7 patient support for Tool A suggests a more robust and readily available support infrastructure.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | ZEUS System | prolaio eVO2peak Module |
|---|---|---|
| Primary Function | AI-powered software analyzing ECG data from wearable biosensors for long-term continuous cardiac monitoring, aiding in the detection and characterization of arrhythmias like Atrial Fibrillation. | FDA-cleared software to estimate peak oxygen consumption (eVO2peak) using real-world patient data for cardiovascular research and care. |
| Company | iRhythm Technologies | Prolaio |
| Key Features | AI-powered arrhythmia detection, continuous ECG monitoring (up to 14 days), cloud-based data analytics, detection and characterization of Atrial Fibrillation (AFib), preliminary report generation for physicians, integration with Zio Watch and Zio monitors, support for symptomatic and asymptomatic cardiac events, HL7-based EHR integration. | Estimates peak oxygen consumption (eVO2peak), utilizes demographic data, single-lead ECG, and triaxial accelerometry inputs, processes data from qualified third-party FDA-cleared wearable medical sensors, applies a locked deep-learning model for eVO2peak estimation, provides information as an adjunctive aid in clinical evaluation, enables high-density, longitudinal data collection, leverages real-world patient data and insights, features FDA-cleared software and proprietary algorithms. |
| Categories | Cardiology AI, Wearables & Remote Monitoring (RPM) | Cardiology AI, Clinical Decision Support & Reference |
| Specialties | Cardiology, Family Medicine, Internal Medicine | Cardiology, Physical Medicine & Rehab, Sports Medicine |
Videos
Demos, reviews, and walkthroughs featuring ZEUS System and prolaio eVO2peak Module.
Frequently Asked Questions
More Comparisons
More matchups featuring ZEUS System or prolaio eVO2peak Module
Backers
Who funded each tool's parent company.